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Most kidney disorders involve some degree of inflammation, i.e. induction of pro-inflammatory mediators and
leukocyte recruitment. But what are the factors that determine inflammation as a trigger or a consequence of
kidney injury? Which types of renal inflammation can be targeted by the novel more selective immunosuppressive
and anti-inflammatory agents? How to dissect the mechanisms behind innate and adaptive immune responses that
are orchestrated inside or outside the kidney but both cause renal immunopathology i.e. renal inflammation? How
to dissect leukocytic cell infiltrates into pro-inflammatory leukocytes from anti-inflammatory and pro-regenerative
leukocytes? How to dissect leukocytes that support epithelial repair from those that promote renal fibrosis. The
term ‘renal inflammation’ has moved far beyond the descriptive category of ‘mixed leukocytic cell infiltrates’ as
commonly described in kidney biopsies. It is time to face the complexity of renal inflammation to finally benefit
from the new age of novel immunomodulatory medicines.
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that helps to control dangers that disrupt kidney homeo-
stasis [1,2]. Historically, inflammation was clinically de-
fined by the combination of rubor, calor, dolor, tumor, and
functio laesa. In the 18th and 19th century the concept of
cellular pathology evolved and since then leukocytic cell
infiltrates were taken as a hallmark of what we call tissue
inflammation. Until today the presence of increased num-
bers of leukocytes in body fluids such as blood, liquor,
urine or within joints or the pleural and peritoneal cavity
is taken as a biomarker of inflammation. Based on the
work of Jenner, Behring, Kitasato, Ehrlich, and Lahnsteiner
immunological memory was discovered and first thought
to solely depend on humoral factors, the immunoglobulins
[3]. This view was subsequently refined by the discovery of
the T and B lymphocytes and later by the identification
and characterization of antigen-presenting cells [3]. In the
20th century research in the field of immunology was
dominated by the growing understanding of the complex-
ity of antigen-specific ‘adaptive’ immunity, immune toler-
ance, and immune memory, a field much stimulated byCorrespondence: hjanders@med.uni-muenchen.de
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reproduction in any medium, provided the orthe implementation of organ transplantation into clinical
practice [3].
Despite seminal advances on kidney physiology and
pathology in the 19th century nephrology as a distinct
medical discipline did not evolve before the second part
of the 20th century, largely driven by technical advances
in renal replacement therapies [4,5]. The growing under-
standing of renal inflammation as a pathway to chronic
kidney disease was dominated by the pathophysiological
concepts of immune complex disease, antigen-specific
immunity in interstitial nephritis, and alloimmunity of the
kidney allograft [6]. It was not before the discovery of the
complement system, the Fc receptors, and the cytokines
that innate immunity became a central topic of interest
[6]. Chemokines raised further attention on the mecha-
nisms of neutrophil and macrophage recruitment, which,
obviously, contributed to immunopathology of the kidney
in an antigen-independent manner [7].
However, upon the discovery of the Toll-like receptors
[8], the RIG-like helicases [9], and the inflammasomes
[10] in the 1990s the scientific community shifted its full
attention towards the innate immune system [11]. The
innate and the adaptive immune system are different from
many points of view as listed in Table 1. The evolution
of the innate immune system dates back to the first singlehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Differences in innate and adaptive immunity
Innate immunity Adaptive immunity
Recognition receptors (R) Complement-R B cell receptors
Mannose-R T cell receptors
Toll-like-R MHC I
Inflammasomes MHCII
Low affinity immunoglobulins High affinity IgG
Receptor clonality Non-clonal clonal
Receptor genes Single gene, no rearrangement required Encoded in gene segments Rearrangement required
Receptor agonists Molecular patterns Antigenic epitopes
Time delay of response Immediate Delayed
Effector mechanism Opsonization, phagocytosis, granuloma formation,
leukocyte recruitment, complement lysis,
inflammation, healing responses
Clonal expansion of antigen-specific B and T cells,
antigen-specific immunoglobulins
Paradigmatic kidney diseases Urinary tract infection, acute kidney injury,
glomerulosclerosis, tubulointerstitial fibrosis,
crystal nephropathies C3 glomerulopathy
IC glomerulonephritis, allograft rejection, interstitial nephritis
IC immune complex.
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fore the appearance of the jawed cartilaginous fish around
500 million years ago [12]. Since then evolution has
imprinted a tight connection between innate and adaptive
immune reponses for the sake of most efficient pathogen
control [13]. But what is the impact of the evolving under-
standing of innate immunity on renal science?
Most kidney diseases involve inflammation. Adaptive
immunity predominates in kidney disorders that are
related to foreign antigens (e.g. in postinfectious glom-
erulonephritis) or autoantigens (Table 1). Autoantigens
may come from within the kidney (e.g. in anti-glomerular
basemement membrane glomerulonephritis or renal
transplantation) or from extrarenal sources (e.g. in IgA
nephropathy). As such immune complex-related glom-
erulonephritis, allograft rejection or antigen-mediated
interstitial nephritis are paradigmatic disorders in which
systemic immunosuppression can suppress the immune
responses that are regulated outside the kidney.
Innate immunity is the predominant immune response
in antigen-independent types of inflammation, such as
toxic, ischemic, or traumatic kidney injury, which often
present as acute kidney injury where the inflammatory
component largely determines renal immunopathology
and dysfunction [14]. For example, experimental inter-
ventions that suppress inflammation in acute kidney in-
jury, e.g. by blocking pro-inflammatory cytokines and
chemokines or by ablating pro-inflammatory leukocyte
subsets, largely abrogates tubular cell necrosis and the
clinical syndrome of acute renal failure [15]. Tubular ne-
crosis exposes danger signals from dying tubular cells or
the tubular lumen to Toll-like receptors or the NLRP3
inflammasome in renal dendritic cells, which sets-off the
inflammatory response [16-19]. Also crystal-induced renalinflammation and kidney injury largely depend on NLRP3
inflammasome-mediated induction of interleukin-1β se-
cretion by renal dendritic cells [20]. Innate immunity
also drives C3 glomerulopathy where glomerular com-
plement activation is independent of immune complex
disease [21]. Innate immunity orchestrates immediate host
defense during infective pyelonephritis with uropathogenic
bacteria, which may drive renal abscess formation as a
form of collateral tissue damage [22,23]. Neutrophil re-
cruitment and neutrophil-mediated immunopathology is
a major element of renal immunopathology in renal in-
fection but also in acute tubular necrosis or renal vascu-
litis, in which innate immunity plays a major role. Finally,
even in those diseases that are not directly triggered by
immune mechanisms, innate immunity is at least involved
in that inflammation that comes with tissue remodeling.
Macrophage infiltrates do not always necessarily contribute
to renal injury but also to wound healing [24] as macro-
phage depletion in the healing phase of kidney injury delays
kidney regeneration [25-27]. In addition, the role of such
wound-healing macrophage phenotypes in driving kidney
fibrosis is well established [28]. As such innate immunity is
involved in tissue remodeling of all chronic and progressive
kidney diseases even such as diabetic nephropathy, Alport
nephropathy or polycystic kidney disease [29-32].
But where is the field going? The complex cross-talk
between innate and adaptive immunity remains a chal-
lenge also for the future [33]. For example, ischemia-
reperfusion injury is a trigger of renal allograft rejection
but how does that work mechanistically [34,35]? How
can monocytes confer allorecognition [36]? What is the
role of the recently described innate lymphocytes in kid-
ney disease [37]? How do γδT cells, NKT cells, and B1
cells link innate and adaptive immunity in kidney
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regulatory T cells be used for therapeutic purposes?
What are the innate and what are the adaptive immune
functions of the spectrum of the mononuclear phago-
cyte phenotypes inside the kidney [38]? And finally,
when will we finally implement the novel immunoregu-
latory drugs that are so successful in other medical dis-
ciplines also into treatments for patients with kidney
diseases? These and other exciting questions are
awaiting to be addressed by nephro-immunologists at
the bench and immuno-nephrologists at bedside.
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